熱門資訊> 正文
Salarius Pharmaceuticals重新遵守纳斯达克最低出价要求
2025-09-09 20:09
- Salarius Pharmaceuticals (NASDAQ:SLRX) on Tuesday said it has received notification from Nasdaq that it has regained compliance with the Minimum Bid Price Requirement.
- As disclosed on August 27, Salarius has until October 20, 2025 to regain compliance with the listing rule.
- On January 13, 2025, Salarius announced it had entered into a definitive merger agreement for a business combination with Decoy Therapeutics. Under the agreement, Decoy will merge with a wholly owned subsidiary of Salarius, subject to the closing conditions set forth in the agreement. The newly formed company will be named Decoy Therapeutics.
- SLRX +7.52% premarket to $5.0.
- Source: Press Release
More on Salarius Pharmaceuticals
- Salarius Pharmaceuticals granted additional extension to regain Nasdaq compliance
- Financial information for Salarius Pharmaceuticals
推薦文章
華盛早報 | 亞馬遜加入OpenAI「朋友圈」，股價大漲4%創新高！分析師唱多英偉達市值上8.5萬億美元
美股機會日報 | 大摩警告！若薪酬方案被否，特斯拉或跌超10％；微軟獲批向阿聯酋出口最新款英偉達芯片
美債上演大反攻 「Sell America」大錯特錯! 嘴上喊「美國例外論坍塌」的機構實際上狂買美債?
華盛早報 | 美政府「停擺」逼近歷史記錄！巴菲特卸任前最后財報：伯克希爾3817億美元現金儲備創新高，營業利潤激增34%；美股今起進入冬令時
明略科技-W今日上市：香港公開發售獲4452.86倍認購
新能源汽車「銀十」熱銷 多家車企交付量破紀錄
英偉達市值突破 5 萬億：回顧它與加密貨幣的曾經蜜月期
「股神」巴菲特旗下伯克希爾財報出爐，現金儲備超3800億美元創歷史記錄！速看前五大持倉
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
